First-line AML: does add-on clofarabine improve survival in young adults?

Access to the full content of this site is available only to registered healthcare professionals. Register to read more


  • Clofarabine reduces risk for relapse in younger adults with previously untreated acute myeloid leukemia (AML), but only improves survival in selected groups of intermediate-risk patients with AML.

Why this matters

  • Clofarabine has not previously been evaluated in first-line therapy for younger adults with AML.

Study design

  • Randomized study to compare induction regimens in 795 patients with previously untreated AML/high-risk myelodysplastic syndrome.
  • Treatment: idarubicine-cytarabine for cycle 1 + amsacrine-cytarabine for cycle 2, with (n=393)/without (n=402) clofarabine in both cycles; consolidation therapy was chemotherapy with/without hematopoietic stem cell transplantation (HSCT).
  • Funding: Sanofi Pharma.

Key results

  • Complete remission after cycle 1: 75% with clo...